AstraZeneca's Diabetes Drug and Increased Risk of Heart Failure
Written By: Rheingold, Giuffra, Ruffo & Plotkin LLP
Are diabetes drugs putting you at greater risk of heart failure? Data published by the respected New England Journal of Medicine unveiled a rise in hospitalizations for heart failures amongst users of AstraZeneca's drug, saxagliptin.
Saxagliptin, more commonly known as Onglyza and Kombiglyze XR, has been widely prescribed to diabetic patients across the country.
Following the concerning data released by the NEJM, the FDA has announced that it is to conduct an investigation into the possible heart risks associated with use of the drug. The firm of Rheingold, Giuffra, Ruffo & Plotkin LLP will follow developments, including any lawsuits, as we have a drug product liability department representing people injured by dangerous drugs.